-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
Transaction marks a significant milestone for DSS's investment in Impact Biomedical and establishes Zoar Limited as an NYSE American-listed pharmaceutical company
Zoar Limited ordinary shares expected to begin trading under ticker symbol "ZOAR" on November 18, 2026
WEST HENRIETTA, NY / ACCESS Newswire / November 18, 2026 / DSS, Inc. (NYSE American:DSS) ("DSS" or the "Company") today announced that Impact Biomedical Inc. ("Impact Biomedical"), in which DSS has held a majority ownership interest, has completed its previously announced business combination with Zoar Limited ("Zoar") and Zoar Labs Limited ("Zoar Labs").
The business combination was approved by Impact Biomedical stockholders at a special meeting on November 13, 2026. Following completion, Impact Biomedical became a wholly owned subsidiary of Zoar Limited and was renamed Zoar USA Inc. Each outstanding share of Impact Biomedical common stock was converted into the right to receive one ordinary share of Zoar Limited, pursuant to the transaction terms.
Zoar Limited ordinary shares are expected to begin trading on the NYSE American under the ticker symbol "ZOAR" on November 18, 2026. The completion of the transaction provides a new publicly traded structure for the business and represents an important milestone in DSS's investment history with Impact Biomedical.
Jason Grady, Chief Executive Officer of DSS, commented:
"The successful completion of this transaction is a meaningful milestone for DSS and reflects our continued focus on advancing the potential of our portfolio investments. Through Impact Biomedical, DSS has supported the pursuit of opportunities intended to create long-term shareholder value. The combination with Zoar introduces an established international pharmaceutical operating business to the public markets and provides a new platform for future growth. We believe this development represents an important step in the evolution of our investment and reinforces our commitment to strategic transactions that can strengthen DSS's long-term position and create opportunities for our shareholders."
Zoar is a global pharmaceutical company focused on the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and intermediates, as well as contract development and manufacturing services. Zoar Labs reported approximately $651.7 million in revenue and $77.7 million in net income for the fiscal year ended March 31, 2026, representing year-over-year increases of approximately 17.1% and 23.9%, respectively. These figures relate to Zoar Labs and do not represent DSS's consolidated financial results.
The transaction does not change DSS's NYSE American ticker symbol, "DSS." DSS will provide additional information concerning the transaction's impact on its investment holdings and financial reporting, as appropriate, through its SEC filings.
About DSS, Inc.
DSS, Inc. (NYSE American:DSS) is a diversified company with interests across multiple business sectors. For additional information, visit www.dssworld.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements concerning the expected commencement of trading of Zoar Limited ordinary shares, Zoar's business prospects, the potential benefits of the business combination, and potential long-term benefits to DSS and its shareholders. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including market and trading conditions, the ability of Zoar to maintain its listing and execute its business strategy, regulatory and operational risks, and uncertainties relating to DSS's investment and financial reporting. Additional risks are described in DSS's filings with the Securities and Exchange Commission and in filings relating to the business combination. Forward-looking statements speak only as of the date hereof, and DSS undertakes no obligation to update them except as required by law.
Investor Relations
DSS, Inc. | [email protected]
www.dssworld.com
SOURCE: DSS, Inc.
View the original press release on ACCESS Newswire
F.Wilson--AT